Zoetis Inc (ZTS) carries a ŷRobot AI score of 58 out of 100. The model's fair value estimate is $79.53, 0.2% above the last close of $79.38. The chart signal reads Bearish.
| Metric | ZTS |
|---|---|
| AI score | 58 / 100 |
| Chart signal | Bearish |
| Fair value estimate | $79.53 |
| Upside to fair value | 0.2% |
| Previous close | $79.38 |
| P/E | 11.47 |
| Price / sales | 3.00 |
| Market cap | $32.40B |
| EPS | 6.13 |
| Revenue growth | 5.5% |
| 1-year price change | 5.1% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, UnitedHealth Group Incorporated, Merck & Company Inc, Novartis AG ADR.
As of Oct 16, 2026, ŷRobot's fair-value model estimates Zoetis Inc (ZTS) at $79.53 against a last close of $79.38, implying 0.2% upside to the model's estimate.
The chart-signal model classifies ZTS as Neutral as of Oct 16, 2026, with a signal score of -0.10 on a -1 to 1 scale.
ZTS scores 58 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Oct 16, 2026.
ZTS trades at 11.5 times earnings and 3.0 times sales as of Oct 16, 2026.
ŷRobot's seasonal forecast curve for ZTS reads -1.0% at 30 days, +3.6% at 90 days, and +5.1% at one year as of Oct 16, 2026. Seasonal tendencies are historical patterns, not predictions.
Zoetis Inc's revenue growth is +5.5% and free-cash-flow growth is +3.4% on the latest reported figures.
ZTS chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.